This is a massive step forward for vascular treatment. EV2 Technologies, Inc. received a two-year, $2.1 million Small Business Innovation Research Direct-to-Phase II award from the National Institutes of Health National Heart Lung and Blood Institute for its Biocarpet device.
Funding and Development Plans
EV2 Technologies received the two-year, $2.1 million Small Business Innovation Research Direct-to-Phase II award from the National Institutes of Health National Heart Lung and Blood Institute. The funding will support refining the manufacturing process, redesigning the thermal balloon catheter, and designing a control console compatible with any catheterization laboratory.
The company also plans benchtop testing followed by a six-month study to assess the device's safety and efficacy in an animal model. The award marks a turning point allowing the company to formally license the underlying technology from the University.
About Biocarpet and Peripheral Artery Disease
Peripheral artery disease is present in more than 12 million Americans and 200 million individuals worldwide. Biocarpet is a fully biodegradable sheet that unfurls inside blood vessels to relieve dangerous blockages caused by the disease.
While stents are commonly used to treat the disease, these devices are not compatible with small or winding arteries and often fail after they are implanted, particularly in vessels that cross joints.
Our take
EV2 Technologies is using the $2.1 million NIH award to transition its technology through manufacturing refinements, animal testing, and formal licensing from the University of Pittsburgh. Combining federal grants with private venture capital fundraising gives the startup multiple avenues to pursue as it advances the Biocarpet device.
Key facts and where they come from
- EV2 Technologies received a $2.1 million SBIR award from the NIH NHLBI.
received a two-year, $2.1 million Small Business Innovation Research Direct-to-Phase II (SBIR) award from the National Institutes of Health (NIH)
- Biocarpet is a fully biodegradable sheet designed to relieve blockages from peripheral artery disease.
Biocarpet, a fully biodegradable sheet that unfurls inside blood vessels to relieve dangerous blockages caused by PAD.
The catch
- The announcement does not detail the exact timeline or cost for bringing Biocarpet to human clinical trials.
- The company has not disclosed the financial terms of formally licensing the underlying technology from the University.
